Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.40), $0.02 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.17 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Benchmark Starts Boyd Gaming (BYD) at Buy